|
Sorafenib and irinotecan combination for pre-treated RAS-mutated metastatic colorectal cancer patients: A multicentre randomized phase II trial (NEXIRI 2). |
|
|
Honoraria - Lilly; Roche; Sanofi |
Consulting or Advisory Role - Lilly; Roche; Sanofi |
Research Funding - Bayer (Inst) |
Travel, Accommodations, Expenses - Ipsen; Novartis |
|
Christelle De La Fouchardiere |
Consulting or Advisory Role - Bayer; Celgene |
Travel, Accommodations, Expenses - Amgen; Celgene; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - Bayer; Celgene; Ipsen; Lilly; Novartis; Roche; Sanofi |
|
|
No Relationships to Disclose |
|
|
Honoraria - Celgene; Merck; Roche; Sanofi |
Consulting or Advisory Role - Celgene; Merck; Roche; Sanofi |
Speakers' Bureau - Celgene; Merck; Roche; Sanofi |
Travel, Accommodations, Expenses - Celgene; Merck; Novartis; Roche; Sanofi |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bayer |
Research Funding - Bayer (Inst) |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bayer; Lilly; Merck Serono; Roche; Sanofi |
Consulting or Advisory Role - Lilly; Sanofi |
|
|
|
Consulting or Advisory Role - Bayer |
|
|
Consulting or Advisory Role - Merck Serono; Novartis; Roche |
Speakers' Bureau - Bayer; Lilly |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Bayer; Merck; Roche; Sanofi |
|
|
Honoraria - Amgen; Celgene; Lilly; Merck; Roche |
Consulting or Advisory Role - Amgen; Celgene; Merck; Roche |
|
|
Speakers' Bureau - Novartis; Roche; Sanofi |
Travel, Accommodations, Expenses - Ipsen; Novartis; Sanofi |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bayer |
Research Funding - Bayer (Inst) |